Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ceftolozane/Tazobactam + Metronidazole vs Meropenem in Pediatric cIAI
NCT03217136Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2018
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 2 trial of ceftolozane + tazobactam in Intra-abdominal infection (IAI), sponsored by Merck & Co.. Started Apr 2018; status: completed.
02
Drugs
ceftolozane + tazobactam
03
Conditions
Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on NCT03217136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217136.